TABLE 5

Phase Ic study in patients with idiopathic pulmonary fibrosis: pharmacokinetic parameters of BI 1015550 18 mg twice daily

Parameter (unit)gMean+gCV (%)
Day 1#
Cmax (nmol·L−1)27723.1
 AUCτ,1 (nmol·h·L−1)199018.2
Day 14
Cmax,ss (nmol·L−1)46041.7
 AUCτ,ss (nmol·h·L−1)372049.5

n=10. gMean: geometric mean; gCV: geometric coefficient of variation; Cmax: maximum measured concentration of the analyte in plasma; AUCτ,1: area under the concentration–time curve of the analyte in plasma over a uniform dosing interval τ after administration of the first dose; Cmax,ss: maximum measured concentration of analyte in plasma at steady state over a uniform dosing interval τ; AUCτ,ss: area under the concentration–time curve of the analyte in plasma at steady state over a uniform dosing interval τ at steady state. #: after the first dose; : at steady state; +: n=10.